Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 311 entries
Sorted by: Best Match Show Resources per page
[The mechanism of initiation of supraventricular paroxysmal tachycardia].

Atti della Societa italiana di cardiologia

Ballarino M, Rumolo R.
PMID: 5743828
Atti Soc Ital Cardiol. 1968;2:134-5.

No abstract available.

Cite
Ballarino M, Rumolo R. Le modalità di inizio delle tachicardie parossistiche sopraventricolari. [The mechanism of initiation of supraventricular paroxysmal tachycardia]. Atti Soc Ital Cardiol. 1968;2:134-5
Ballarino, M., & Rumolo, R. (1968). Le modalità di inizio delle tachicardie parossistiche sopraventricolari. [The mechanism of initiation of supraventricular paroxysmal tachycardia]. Atti della Societa italiana di cardiologia, 2134-5.
Ballarino, M, and Rumolo, R. "Le modalità di inizio delle tachicardie parossistiche sopraventricolari." [The mechanism of initiation of supraventricular paroxysmal tachycardia]. Atti della Societa italiana di cardiologia vol. 2 (1968): 134-5.
Ballarino M, Rumolo R. Le modalità di inizio delle tachicardie parossistiche sopraventricolari. [The mechanism of initiation of supraventricular paroxysmal tachycardia]. Atti Soc Ital Cardiol. 1968;2:134-5. Italian. PMID: 5743828.
Copy Download .nbib Format: NLM
What's the use of Archimedes?.

Archives of disease in childhood

Rudolf M, Rowland G, Das G, Gardiner S, Khan F, Krishnan V, Mylona F, Preece J, Omosigho C, Willey C, Williamson A.
PMID: 12138076
Arch Dis Child. 2002 Aug;87(2):168-9; discussion 168-9. doi: 10.1136/adc.87.2.168.

No abstract available.

Cite
Rudolf M, Rowland G, Das G, et al. What's the use of Archimedes?. Arch Dis Child. 2002;87(2):168-9; discussion 168-9doi: 10.1136/adc.87.2.168.
Rudolf, M., Rowland, G., Das, G., Gardiner, S., Khan, F., Krishnan, V., Mylona, F., Preece, J., Omosigho, C., Willey, C., & Williamson, A. (2002). What's the use of Archimedes?. Archives of disease in childhood, 87(2), 168-9; discussion 168-9. https://doi.org/10.1136/adc.87.2.168
Rudolf, M, et al. "What's the use of Archimedes?." Archives of disease in childhood vol. 87,2 (2002): 168-9; discussion 168-9. doi: https://doi.org/10.1136/adc.87.2.168
Rudolf M, Rowland G, Das G, Gardiner S, Khan F, Krishnan V, Mylona F, Preece J, Omosigho C, Willey C, Williamson A. What's the use of Archimedes?. Arch Dis Child. 2002 Aug;87(2):168-9; discussion 168-9. doi: 10.1136/adc.87.2.168. PMID: 12138076; PMCID: PMC1719176.
Copy Download .nbib Format: NLM
Study of porous silicon nanostructures as hydrogen reservoirs.

The journal of physical chemistry. B

Lysenko V, Bidault F, Alekseev S, Zaitsev V, Barbier D, Turpin C, Geobaldo F, Rivolo P, Garrone E.
PMID: 16853549
J Phys Chem B. 2005 Oct 27;109(42):19711-8. doi: 10.1021/jp053007h.

The amount of hydrogen present in porous silicon (PS) nanostructures is analyzed in detail. Concentration of atomic hydrogen chemically bound to the specific surface of PS is quantitatively evaluated by means of attenuated total reflection infrared (ATR-IR) spectroscopy and...

Cite
Lysenko V, Bidault F, Alekseev S, et al. Study of porous silicon nanostructures as hydrogen reservoirs. J Phys Chem B. 2005;109(42):19711-8doi: 10.1021/jp053007h.
Lysenko, V., Bidault, F., Alekseev, S., Zaitsev, V., Barbier, D., Turpin, C., Geobaldo, F., Rivolo, P., & Garrone, E. (2005). Study of porous silicon nanostructures as hydrogen reservoirs. The journal of physical chemistry. B, 109(42), 19711-8. https://doi.org/10.1021/jp053007h
Lysenko, Vladimir, et al. "Study of porous silicon nanostructures as hydrogen reservoirs." The journal of physical chemistry. B vol. 109,42 (2005): 19711-8. doi: https://doi.org/10.1021/jp053007h
Lysenko V, Bidault F, Alekseev S, Zaitsev V, Barbier D, Turpin C, Geobaldo F, Rivolo P, Garrone E. Study of porous silicon nanostructures as hydrogen reservoirs. J Phys Chem B. 2005 Oct 27;109(42):19711-8. doi: 10.1021/jp053007h. PMID: 16853549.
Copy Download .nbib Format: NLM
Erratum to: Rheumatology training experience across Europe: analysis of core competences.

Arthritis research & therapy

Sivera F, Ramiro S, Cikes N, Cutolo M, Dougados M, Gossec L, Kvien TK, Lundberg IE, Mandl P, Moorthy A, Panchal S, da Silva JA, Bijlsma JW.
PMID: 27993150
Arthritis Res Ther. 2016 Dec 19;18(1):300. doi: 10.1186/s13075-016-1199-3.

No abstract available.

Cite
Sivera F, Ramiro S, Cikes N, et al. Erratum to: Rheumatology training experience across Europe: analysis of core competences. Arthritis Res Ther. 2016;18(1):300doi: 10.1186/s13075-016-1199-3.
Sivera, F., Ramiro, S., Cikes, N., Cutolo, M., Dougados, M., Gossec, L., Kvien, T. K., Lundberg, I. E., Mandl, P., Moorthy, A., Panchal, S., da Silva, J. A., Bijlsma, J. W. (2016). Erratum to: Rheumatology training experience across Europe: analysis of core competences. Arthritis research & therapy, 18(1), 300. https://doi.org/10.1186/s13075-016-1199-3
Sivera, Francisca, et al. "Erratum to: Rheumatology training experience across Europe: analysis of core competences." Arthritis research & therapy vol. 18,1 (2016): 300. doi: https://doi.org/10.1186/s13075-016-1199-3
Sivera F, Ramiro S, Cikes N, Cutolo M, Dougados M, Gossec L, Kvien TK, Lundberg IE, Mandl P, Moorthy A, Panchal S, da Silva JA, Bijlsma JW. Erratum to: Rheumatology training experience across Europe: analysis of core competences. Arthritis Res Ther. 2016 Dec 19;18(1):300. doi: 10.1186/s13075-016-1199-3. PMID: 27993150; PMCID: PMC5165707.
Copy Download .nbib Format: NLM
Graphene/Ruthenium Active Species Aerogel as Electrode for Supercapacitor Applications.

Materials (Basel, Switzerland)

Gigot A, Fontana M, Pirri CF, Rivolo P.
PMID: 29301192
Materials (Basel). 2017 Dec 30;11(1). doi: 10.3390/ma11010057.

Ruthenium active species containing Ruthenium Sulphide (RuS₂) is synthesized together with a self-assembled reduced graphene oxide (RGO) aerogel by a one-pot hydrothermal synthesis. Ruthenium Chloride and L-Cysteine are used as reactants. The hydrothermal synthesis of the innovative hybrid material...

Cite
Gigot A, Fontana M, Pirri CF, et al. Graphene/Ruthenium Active Species Aerogel as Electrode for Supercapacitor Applications. Materials (Basel). 2017;11(1)doi: 10.3390/ma11010057.
Gigot, A., Fontana, M., Pirri, C. F., & Rivolo, P. (2017). Graphene/Ruthenium Active Species Aerogel as Electrode for Supercapacitor Applications. Materials (Basel, Switzerland), 11(1), . https://doi.org/10.3390/ma11010057
Gigot, Arnaud, et al. "Graphene/Ruthenium Active Species Aerogel as Electrode for Supercapacitor Applications." Materials (Basel, Switzerland) vol. 11,1 (2017). doi: https://doi.org/10.3390/ma11010057
Gigot A, Fontana M, Pirri CF, Rivolo P. Graphene/Ruthenium Active Species Aerogel as Electrode for Supercapacitor Applications. Materials (Basel). 2017 Dec 30;11(1). doi: 10.3390/ma11010057. PMID: 29301192; PMCID: PMC5793555.
Copy Download .nbib Format: NLM
Cancer vaccination causes prolonged FDG accumulation in subcutaneous tissue.

Nuklearmedizin. Nuclear medicine

Kahnert K, Kauffmann-Guerrero D, Tufman A, Borgmeier A, Huber RM, Berger F.
PMID: 28429815
Nuklearmedizin. 2017 Apr 21; doi: 10.3413/Nukmed-0868-16-12. Epub 2017 Apr 21.

No abstract available.

Cite
Kahnert K, Kauffmann-Guerrero D, Tufman A, et al. Cancer vaccination causes prolonged FDG accumulation in subcutaneous tissue. Nuklearmedizin. 2017;doi: 10.3413/Nukmed-0868-16-12.
Kahnert, K., Kauffmann-Guerrero, D., Tufman, A., Borgmeier, A., Huber, R. M., & Berger, F. (2017). Cancer vaccination causes prolonged FDG accumulation in subcutaneous tissue. Nuklearmedizin. Nuclear medicine, . https://doi.org/10.3413/Nukmed-0868-16-12
Kahnert, Kathrin, et al. "Cancer vaccination causes prolonged FDG accumulation in subcutaneous tissue." Nuklearmedizin. Nuclear medicine vol. (2017). doi: https://doi.org/10.3413/Nukmed-0868-16-12
Kahnert K, Kauffmann-Guerrero D, Tufman A, Borgmeier A, Huber RM, Berger F. Cancer vaccination causes prolonged FDG accumulation in subcutaneous tissue. Nuklearmedizin. 2017 Apr 21; doi: 10.3413/Nukmed-0868-16-12. Epub 2017 Apr 21. PMID: 28429815.
Copy Download .nbib Format: NLM
Correction: Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea.

PLoS medicine

Sissoko D, Laouenan C, Folkesson E, M'Lebing AB, Beavogui AH, Baize S, Camara AM, Maes P, Shepherd S, Danel C, Carazo S, Conde MN, Gala JL, Colin G, Savini H, Bore JA, Le Marcis F, Koundouno FR, Petitjean F, Lamah MC, Diederich S, Tounkara A, Poelart G, Berbain E, Dindart JM, Duraffour S, Lefevre A, Leno T, Peyrouset O, Irenge L, Bangoura N, Palich R, Hinzmann J, Kraus A, Barry TS, Berette S, Bongono A, Camara MS, Munoz VC, Doumbouya L, Harouna S, Kighoma PM, Koundouno FR, Lolamou R, Loua CM, Massala V, Moumouni K, Provost C, Samake N, Sekou C, Soumah A, Arnould I, Komano MS, Gustin L, Berutto C, Camara D, Camara FS, Colpaert J, Delamou L, Jansson L, Kourouma E, Loua M, Malme K, Manfrin E, Maomou A, Milinouno A, Ombelet S, Sidiboun AY, Verreckt I, Yombouno P, Bocquin A, Carbonnelle C, Carmoi T, Frange P, Mely S, Nguyen VK, Pannetier D, Taburet AM, Treluyer JM, Kolie J, Moh R, Gonzalez MC, Kuisma E, Liedigk B, Ngabo D, Rudolf M, Thom R, Kerber R, Gabriel M, Di Caro A, Wölfel R, Badir J, Bentahir M, Deccache Y, Dumont C, Durant JF, El Bakkouri K, Uwamahoro MG, Smits B, Toufik N, Van Cauwenberghe S, Ezzedine K, D'Ortenzio E, Pizarro L, Etienne A, Guedj J, Fizet A, de Sainte Fare EB, Murgue B, Tran-Minh T, Rapp C, Piguet P, Poncin M, Draguez B, Duverger TA, Barbe S, Baret G, Defourny I, Carroll M, Raoul H, Augier A, Eholie SP, Yazdanpanah Y, Levy-Marchal C, Antierrens A, Van Herp M, Günther S, de Lamballerie X, Keïta S, Mentre F, Anglaret X, Malvy D.
PMID: 27046271
PLoS Med. 2016 Apr 05;13(4):e1002009. doi: 10.1371/journal.pmed.1002009. eCollection 2016 Apr.

[This corrects the article DOI: 10.1371/journal.pmed.1001967.].

Cite
Sissoko D, Laouenan C, Folkesson E, et al. Correction: Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea. PLoS Med. 2016;13(4):e1002009doi: 10.1371/journal.pmed.1002009.
Sissoko, D., Laouenan, C., Folkesson, E., M'Lebing, A. B., Beavogui, A. H., Baize, S., Camara, A. M., Maes, P., Shepherd, S., Danel, C., Carazo, S., Conde, M. N., Gala, J. L., Colin, G., Savini, H., Bore, J. A., Le Marcis, F., Koundouno, F. R., Petitjean, F., Lamah, M. C., Diederich, S., Tounkara, A., Poelart, G., Berbain, E., Dindart, J. M., Duraffour, S., Lefevre, A., Leno, T., Peyrouset, O., Irenge, L., Bangoura, N., Palich, R., Hinzmann, J., Kraus, A., Barry, T. S., Berette, S., Bongono, A., Camara, M. S., Munoz, V. C., Doumbouya, L., Harouna, S., Kighoma, P. M., Koundouno, F. R., Lolamou, R., Loua, C. M., Massala, V., Moumouni, K., Provost, C., Samake, N., Sekou, C., Soumah, A., Arnould, I., Komano, M. S., Gustin, L., Berutto, C., Camara, D., Camara, F. S., Colpaert, J., Delamou, L., Jansson, L., Kourouma, E., Loua, M., Malme, K., Manfrin, E., Maomou, A., Milinouno, A., Ombelet, S., Sidiboun, A. Y., Verreckt, I., Yombouno, P., Bocquin, A., Carbonnelle, C., Carmoi, T., Frange, P., Mely, S., Nguyen, V. K., Pannetier, D., Taburet, A. M., Treluyer, J. M., Kolie, J., Moh, R., Gonzalez, M. C., Kuisma, E., Liedigk, B., Ngabo, D., Rudolf, M., Thom, R., Kerber, R., Gabriel, M., Di Caro, A., Wölfel, R., Badir, J., Bentahir, M., Deccache, Y., Dumont, C., Durant, J. F., El Bakkouri, K., Uwamahoro, M. G., Smits, B., Toufik, N., Van Cauwenberghe, S., Ezzedine, K., D'Ortenzio, E., Pizarro, L., Etienne, A., Guedj, J., Fizet, A., de Sainte Fare, E. B., Murgue, B., Tran-Minh, T., Rapp, C., Piguet, P., Poncin, M., Draguez, B., Duverger, T. A., Barbe, S., Baret, G., Defourny, I., Carroll, M., Raoul, H., Augier, A., Eholie, S. P., Yazdanpanah, Y., Levy-Marchal, C., Antierrens, A., Van Herp, M., Günther, S., de Lamballerie, X., Keïta, S., Mentre, F., Anglaret, X., Malvy, D. (2016). Correction: Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea. PLoS medicine, 13(4), e1002009. https://doi.org/10.1371/journal.pmed.1002009
Sissoko, Daouda, et al. "Correction: Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea." PLoS medicine vol. 13,4 (2016): e1002009. doi: https://doi.org/10.1371/journal.pmed.1002009
Sissoko D, Laouenan C, Folkesson E, M'Lebing AB, Beavogui AH, Baize S, Camara AM, Maes P, Shepherd S, Danel C, Carazo S, Conde MN, Gala JL, Colin G, Savini H, Bore JA, Le Marcis F, Koundouno FR, Petitjean F, Lamah MC, Diederich S, Tounkara A, Poelart G, Berbain E, Dindart JM, Duraffour S, Lefevre A, Leno T, Peyrouset O, Irenge L, Bangoura N, Palich R, Hinzmann J, Kraus A, Barry TS, Berette S, Bongono A, Camara MS, Munoz VC, Doumbouya L, Harouna S, Kighoma PM, Koundouno FR, Lolamou R, Loua CM, Massala V, Moumouni K, Provost C, Samake N, Sekou C, Soumah A, Arnould I, Komano MS, Gustin L, Berutto C, Camara D, Camara FS, Colpaert J, Delamou L, Jansson L, Kourouma E, Loua M, Malme K, Manfrin E, Maomou A, Milinouno A, Ombelet S, Sidiboun AY, Verreckt I, Yombouno P, Bocquin A, Carbonnelle C, Carmoi T, Frange P, Mely S, Nguyen VK, Pannetier D, Taburet AM, Treluyer JM, Kolie J, Moh R, Gonzalez MC, Kuisma E, Liedigk B, Ngabo D, Rudolf M, Thom R, Kerber R, Gabriel M, Di Caro A, Wölfel R, Badir J, Bentahir M, Deccache Y, Dumont C, Durant JF, El Bakkouri K, Uwamahoro MG, Smits B, Toufik N, Van Cauwenberghe S, Ezzedine K, D'Ortenzio E, Pizarro L, Etienne A, Guedj J, Fizet A, de Sainte Fare EB, Murgue B, Tran-Minh T, Rapp C, Piguet P, Poncin M, Draguez B, Duverger TA, Barbe S, Baret G, Defourny I, Carroll M, Raoul H, Augier A, Eholie SP, Yazdanpanah Y, Levy-Marchal C, Antierrens A, Van Herp M, Günther S, de Lamballerie X, Keïta S, Mentre F, Anglaret X, Malvy D. Correction: Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea. PLoS Med. 2016 Apr 05;13(4):e1002009. doi: 10.1371/journal.pmed.1002009. eCollection 2016 Apr. PMID: 27046271; PMCID: PMC4821578.
Copy Download .nbib Format: NLM
Reprint of Low-energy electron potentiometry.

Ultramicroscopy

Jobst J, Kautz J, Mytiliniou M, Tromp RM, van der Molen SJ.
PMID: 29103783
Ultramicroscopy. 2017 Dec;183:8-14. doi: 10.1016/j.ultramic.2017.10.009. Epub 2017 Oct 25.

In a lot of systems, charge transport is governed by local features rather than being a global property as suggested by extracting a single resistance value. Consequently, techniques that resolve local structure in the electronic potential are crucial for...

Cite
Jobst J, Kautz J, Mytiliniou M, et al. Reprint of Low-energy electron potentiometry. Ultramicroscopy. 2017;183:8-14doi: 10.1016/j.ultramic.2017.10.009.
Jobst, J., Kautz, J., Mytiliniou, M., Tromp, R. M., & van der Molen, S. J. (2017). Reprint of Low-energy electron potentiometry. Ultramicroscopy, 1838-14. https://doi.org/10.1016/j.ultramic.2017.10.009
Jobst, Johannes, et al. "Reprint of Low-energy electron potentiometry." Ultramicroscopy vol. 183 (2017): 8-14. doi: https://doi.org/10.1016/j.ultramic.2017.10.009
Jobst J, Kautz J, Mytiliniou M, Tromp RM, van der Molen SJ. Reprint of Low-energy electron potentiometry. Ultramicroscopy. 2017 Dec;183:8-14. doi: 10.1016/j.ultramic.2017.10.009. Epub 2017 Oct 25. PMID: 29103783.
Copy Download .nbib Format: NLM
Points to consider-Raynaud's phenomenon in systemic sclerosis.

Rheumatology (Oxford, England)

Cutolo M, Smith V, Furst DE, Khanna D, Herrick AL.
PMID: 28992170
Rheumatology (Oxford). 2017 Sep 01;56:v45-v48. doi: 10.1093/rheumatology/kex199.

RP is an exaggerated vasospastic response to cold or emotion. Randomized, double-blind, placebo-controlled trials with either parallel group or cross-over trials should be mainly considered. Cross-over design, which is good for early phase trials of immediate or very short-term...

Cite
Cutolo M, Smith V, Furst DE, et al. Points to consider-Raynaud's phenomenon in systemic sclerosis. Rheumatology (Oxford). 2017;56:v45-v48doi: 10.1093/rheumatology/kex199.
Cutolo, M., Smith, V., Furst, D. E., Khanna, D., & Herrick, A. L. (2017). Points to consider-Raynaud's phenomenon in systemic sclerosis. Rheumatology (Oxford, England), 56v45-v48. https://doi.org/10.1093/rheumatology/kex199
Cutolo, Maurizio, et al. "Points to consider-Raynaud's phenomenon in systemic sclerosis." Rheumatology (Oxford, England) vol. 56 (2017): v45-v48. doi: https://doi.org/10.1093/rheumatology/kex199
Cutolo M, Smith V, Furst DE, Khanna D, Herrick AL. Points to consider-Raynaud's phenomenon in systemic sclerosis. Rheumatology (Oxford). 2017 Sep 01;56:v45-v48. doi: 10.1093/rheumatology/kex199. PMID: 28992170; PMCID: PMC5850109.
Copy Download .nbib Format: NLM
Patient-physician collaboration in rheumatology: a necessity.

RMD open

Nikiphorou E, Alunno A, Carmona L, Kouloumas M, Bijlsma J, Cutolo M.
PMID: 29152329
RMD Open. 2017 Jul 18;3(1):e000499. doi: 10.1136/rmdopen-2017-000499. eCollection 2017.

Over the past few decades, there has been significant and impressive progress in the understanding and management of rheumatic diseases. One of the key reasons for succeeding in making this progress has been the increasingly stronger partnership between physicians...

Cite
Nikiphorou E, Alunno A, Carmona L, et al. Patient-physician collaboration in rheumatology: a necessity. RMD Open. 2017;3(1):e000499doi: 10.1136/rmdopen-2017-000499.
Nikiphorou, E., Alunno, A., Carmona, L., Kouloumas, M., Bijlsma, J., & Cutolo, M. (2017). Patient-physician collaboration in rheumatology: a necessity. RMD open, 3(1), e000499. https://doi.org/10.1136/rmdopen-2017-000499
Nikiphorou, Elena, et al. "Patient-physician collaboration in rheumatology: a necessity." RMD open vol. 3,1 (2017): e000499. doi: https://doi.org/10.1136/rmdopen-2017-000499
Nikiphorou E, Alunno A, Carmona L, Kouloumas M, Bijlsma J, Cutolo M. Patient-physician collaboration in rheumatology: a necessity. RMD Open. 2017 Jul 18;3(1):e000499. doi: 10.1136/rmdopen-2017-000499. eCollection 2017. PMID: 29152329; PMCID: PMC5686831.
Copy Download .nbib Format: NLM
A cellular nonlinear network: real-time technology for the analysis of microfluidic phenomena in blood vessels.

Nanotechnology

Sapuppo F, Bucolo M, Intaglietta M, Fortuna L, Arena P.
PMID: 21727354
Nanotechnology. 2006 Feb 28;17(4):S54-63. doi: 10.1088/0957-4484/17/4/009. Epub 2006 Jan 25.

A new approach to the observation and analysis of dynamic structural and functional parameters in the microcirculation is described. The new non-invasive optical system is based on cellular nonlinear networks (CNNs), highly integrated analogue processor arrays whose processing elements,...

Cite
Sapuppo F, Bucolo M, Intaglietta M, et al. A cellular nonlinear network: real-time technology for the analysis of microfluidic phenomena in blood vessels. Nanotechnology. 2006;17(4):S54-63doi: 10.1088/0957-4484/17/4/009.
Sapuppo, F., Bucolo, M., Intaglietta, M., Fortuna, L., & Arena, P. (2006). A cellular nonlinear network: real-time technology for the analysis of microfluidic phenomena in blood vessels. Nanotechnology, 17(4), S54-63. https://doi.org/10.1088/0957-4484/17/4/009
Sapuppo, F, et al. "A cellular nonlinear network: real-time technology for the analysis of microfluidic phenomena in blood vessels." Nanotechnology vol. 17,4 (2006): S54-63. doi: https://doi.org/10.1088/0957-4484/17/4/009
Sapuppo F, Bucolo M, Intaglietta M, Fortuna L, Arena P. A cellular nonlinear network: real-time technology for the analysis of microfluidic phenomena in blood vessels. Nanotechnology. 2006 Feb 28;17(4):S54-63. doi: 10.1088/0957-4484/17/4/009. Epub 2006 Jan 25. PMID: 21727354.
Copy Download .nbib Format: NLM
Sex hormones and leflunomide treatment of human macrophage cultures: effects on apoptosis.

International journal of clinical and experimental medicine

Montagna P, Brizzolara R, Soldano S, Pizzorni C, Sulli A, Cutolo M.
PMID: 19918315
Int J Clin Exp Med. 2009 Aug 31;2(3):221-32.

In order to establish the possible gender influence on the activity of leflunomide (LEF) in rheumatoid arthritis (RA), we evaluated the proapoptotic activity of the active LEF metabolite A77 1726 (LEF-M), in combination with sex hormones, on cultures of...

Cite
Montagna P, Brizzolara R, Soldano S, et al. Sex hormones and leflunomide treatment of human macrophage cultures: effects on apoptosis. Int J Clin Exp Med. 2009;2(3):221-32
Montagna, P., Brizzolara, R., Soldano, S., Pizzorni, C., Sulli, A., & Cutolo, M. (2009). Sex hormones and leflunomide treatment of human macrophage cultures: effects on apoptosis. International journal of clinical and experimental medicine, 2(3), 221-32.
Montagna, Paola, et al. "Sex hormones and leflunomide treatment of human macrophage cultures: effects on apoptosis." International journal of clinical and experimental medicine vol. 2,3 (2009): 221-32.
Montagna P, Brizzolara R, Soldano S, Pizzorni C, Sulli A, Cutolo M. Sex hormones and leflunomide treatment of human macrophage cultures: effects on apoptosis. Int J Clin Exp Med. 2009 Aug 31;2(3):221-32. PMID: 19918315; PMCID: PMC2777270.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 311 entries